Candida glabrata Nedenli Kan Dolaşımı Enfeksiyonu olan Hastalarda Flukonazol Dozu ile Sağkalım İlişkisi

References (3)

1. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:e1-e50. Sobue S, Tan K, Layton G, Leclerc V, Weil A. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole. Br J Clin Pharmacol 2004;57:773-84.
2. Bergner R, Hoffmann M, Riedel KD, Mikus G, Henrich DM, Haefeli WE, et al. Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg. Nephrol Dial Transplant 2006;21:1019-23. Clinical and Laboratory Standards Institute. Reference method for broth microdilution antifungal susceptibility testing of yeasts; 4th informational supplement. CLSI M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA, 2012.
3. Brosh-Nissimov T, Ben-Ami R. Differential association of fluconazole dose and dose/MIC ratio with mortality in patients with Candida albicans and non-albicans bloodstream infection. Clin Microbiol Infect 2015;21:1011-7. Fernández-Ruiz M, Guinea J, Lora-Pablos D, Zaragoza Ó Puig-Asensio M, Almirante B, et al. Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance. Clin Microbiol Infect 2017;23:672.e1-672.e11.